Galatea Bio, a Miami, FL-based AI-driven genomic analysis and medical genetic testing firm, raised $25M in funding.
Backers included F-Prime, Helios Digital Ventures, Digitalis Ventures, AME Cloud, CEI Ventures, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics.
The corporate intends to make use of the funds to broaden its clinico-genomics platform to combine multi-modal information and AI-driven functions to refine genetic threat evaluation for Mendelian and complicated ailments, biomarker discovery, and medical trials optimization.
Based in 2021 by Carlos D. Bustamante, Ph.D., CEO and President, Galatea Bio is a biotechnology firm offering precision medication by way of AI-driven information analytics and genomic analysis on large-scale affected person populations, enriched in non-European ancestry. By integrating medical genomics, a proprietary biobank, and AI-enabled algorithms, it accelerates biomarker and drug goal discovery, enhances medical diagnostics, and helps biopharma partnerships.
FinSMEs
27/03/2025
